Hims House Peter Pitts - The Wild West of Compounded GLP-1s
Aug 14, 2025
Peter Pitts, President of the Center for Medicine in the Public Interest and former FDA Associate Commissioner, dives into the unchecked dangers of compounded GLP-1 medications. He critiques the FDA's regulatory gaps and highlights the risks posed by unregulated foreign supply chains. The conversation tackles ethical concerns surrounding corporate funding and the pitfalls of 'phony personalization' in treatment. Pitts debates the future of GLP-1 regulations and the potential for more stringent enforcement or outright bans.
AI Snips
Chapters
Transcript
Episode notes
Unregulated GLP-1s Bypass Core Safeguards
- Pitts says HIMSS pushed boundaries by selling unregulated injectable GLP-1s outside FDA oversight.
- He warns this risks public health because these products lack FDA review, CMC controls, and adverse-event reporting.
Use Existing Rules, Start With The 5% Limit
- Pitts urges the FDA to use existing authority and enforce current compounding rules instead of asking for new powers.
- He highlights the 5% rule as an actionable enforcement lever that is currently neglected.
Enforcement Gap Linked To Resource Limits
- FDA inaction likely stems from resource constraints and prioritization decisions, not necessarily lack of legal tools.
- Pitts argues the agency is understaffed and chooses tasks offering the biggest regulatory impact.